Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <em>RUNX3</em> overexpression
Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <em>RUNX3</em> overexpression
复制标题
Brentuximab vedotin 用于治疗<em>RUNX3</em>过表达的白血病期难治性间变性淋巴瘤激酶阴性间变性大细胞淋巴瘤
DOI:
10.4081/hr.2020.8368
复制
发表时间:
2020
影响因子:
0.9
通讯作者:
Tamura Shinobu
中科院分区:
文献类型:
--
作者:
Yamashita Yusuke;Hori Yoshikazu;Kosako Hideki;Oiwa Takehiro;Warigaya Kenji;Mushino Toshiki;Murata Shogo;Fujimoto Masakazu;Nishikawa Akinori;Murata Shin-ichi;Sonoki Takashi;Tamura Shinobu
登录
查看更多内容
DOI:
--
发表时间:
2010
期刊:
Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis
影响因子:
--
作者:
Ying Lu;Xiaohui Zhao;Endi Wang;Wei Chen;Qin Huang
通讯作者:
Qin Huang
影响因子:
0.9
作者:
Delacruz W;Setlik R;Hassantoufighi A;Daya S;Cooper S;Selby D;Brown A
通讯作者:
Brown A
影响因子:
4.3
作者:
Rodriguez, Roberto;Nademanee, Auayporn;Forman, Stephen J.
通讯作者:
Forman, Stephen J.
影响因子:
3.5
作者:
Xiaohui Zhang;M. Bui;J. Caracciolo;T. Field;Ling Zhang
通讯作者:
Ling Zhang
影响因子:
45.3
作者:
Le Gouill, Steven;Milpied, Noel;Michallet, Mauricette
通讯作者:
Michallet, Mauricette